[8-K] Zevra Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.

Positive

• Press release furnished announcing second-quarter results and corporate updates for the quarter ended June 30, 2025
• Conference call and audio webcast scheduled for investors to hear management commentary on results (Tuesday, August 12, 2025 at 4:30 p.m. ET)

Negative

• No financial statements or tables are included in the Form 8-K itself, limiting what can be assessed from the filing alone
• Press release is furnished, not filed, and is explicitly not incorporated by reference, which limits reliance on the Form 8-K as a complete disclosure of results

Insights

Financial Analyst

TL;DR: Routine earnings release furnished; the 8-K contains no financial tables, limiting immediate analysis from the filing alone.

Zevra furnished a press release announcing second-quarter results for the period ended June 30, 2025 and scheduled an investor webcast the same day. Because the release is furnished as Exhibit 99.1 and expressly not filed or incorporated by reference, analysts must review the exhibit or webcast to obtain the actual metrics. On the face of this Form 8-K the disclosure is procedural and provides notice rather than detailed financial information.

Corporate Governance Expert

TL;DR: Filing follows standard Form 8-K practice; signature by finance officer indicates procedural compliance.

The company adhered to standard disclosure practice by furnishing a press release and identifying the exhibit. The Form 8-K includes a corporate officer signature, confirming the registrant's authorization of the report. The filing explicitly states the exhibit is furnished and not filed, which is an important governance detail for how the content is treated legally and for incorporation into future filings.

false000143464700014346472025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________________________________________

FORM 8-K

__________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 12, 2025

__________________________________________________________________________________________ 

Zevra Therapeutics, Inc

(Exact Name of Registrant as Specified in Its Charter)

__________________________________________________________________________________________

Delaware			001-36913			20-5894398
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
1180 Celebration Boulevard, Suite 103, Celebration, FL						34747
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (321) 939-3416

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			ZVRA			The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02          Results of Operations and Financial Condition.

On August 12, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 12, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the press release, furnished as Exhibit 99.1 shall not be deemed “filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of Zevra's filings under the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01          Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

 SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						Zevra Therapeutics, Inc.
Date: August 12, 2025						By:			/s/ Timothy J. Sangiovanni
									Timothy J. Sangiovanni, CPA
									Senior Vice President, Finance and Corporate Controller

FAQ

When did Zevra (ZVRA) announce its Q2 2025 results?

Zevra issued a press release on August 12, 2025 announcing financial results and corporate updates for the quarter ended June 30, 2025.

When is Zevra's conference call and webcast?

The conference call and audio webcast are scheduled for Tuesday, August 12, 2025 at 4:30 p.m. ET.

Where can I find the press release announced in the 8-K?

The press release is furnished as Exhibit 99.1 to this Current Report (Form 8-K).

Does the Form 8-K include Zevra's financial statements or detailed tables?

No. The Form 8-K does not include financial statements or tables; it furnishes a press release that announces the results.

Who signed the Form 8-K for Zevra?

The Form 8-K is signed by Timothy J. Sangiovanni, CPA, Senior Vice President, Finance and Corporate Controller.